Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial

被引：24

作者：

Faivre-Finn, C. ^{[1
,2
]}

Vicente, D. ^{[3
]}

Kurata, T. ^{[4
]}

Planchard, D. ^{[5
]}

Paz-Ares, L. ^{[6
,7
]}

Vansteenkiste, J. F. ^{[8
]}

Spigel, D. R. ^{[9
,10
]}

Garassino, M. C. ^{[11
]}

Reck, M. ^{[12
]}

Senan, S. ^{[13
]}

Naidoo, J. ^{[14
,15
,16
]}

Rimner, A. ^{[16
]}

Wu, Y-L. ^{[17
,18
]}

Gray, J. E. ^{[19
]}

Ozguroglu, M. ^{[20
]}

Lee, K. H. ^{[21
]}

Newton, M. ^{[22
]}

Wang, L. ^{[22
]}

Thiyagarajah, P. ^{[23
]}

Antonia, S. J. ^{[19
]}

机构：

[1] Univ Manchester, Manchester, Lancs, England

[2] Christie NHS Fdn Trust, Manchester, Lancs, England

[3] Hosp Univ Virgen Macarena, Seville, Spain

[4] Kansai Med Univ Hosp, Hirakata, Osaka, Japan

[5] Gustave Roussy, Dept Med Oncol, Thorac Unit, Villejuif, France

[6] Univ Complutense, Hosp Univ 12 Octubre, CiberOnc, Madrid, Spain

[7] CNIO, Madrid, Spain

[8] Univ Hosp KU Leuven, Dept Resp Oncol, Leuven, Belgium

[9] Sarah Cannon Res Inst, Nashville, TN USA

[10] Tennessee Oncol, Nashville, TN USA

[11] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[12] German Ctr Lung Res, Lung Clin Grosshansdorf, Airway Res Ctr North, Grosshansdorf, Germany

[13] Vrije Univ Amsterdam, Amsterdam Univ Med Ctr, Canc Ctr Amsterdam, Dept Radiat Oncol, Amsterdam, Netherlands

[14] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[15] Johns Hopkins Univ, Bloomberg Kimmel Inst Canc Immunotherapy, Baltimore, MD USA

[16] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1275 York Ave, New York, NY 10021 USA

[17] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Dept Pulm Oncol, Guangzhou, Peoples R China

[18] Guangdong Acad Med Sci, Guangzhou, Peoples R China

[19] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[20] Istanbul Univ Cerrahpasa, Cerrahpasa Sch Med, Istanbul, Turkey

[21] Chungbuk Natl Univ, Chungbuk Natl Univ Hosp, Coll Med, Cheongju, South Korea

[22] AstraZeneca, Gaithersburg, MD USA

[23] AstraZeneca, Cambridge, England

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.08.2281

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA49

引用

页码：S1178 / S1179

页数：2

共 50 条

[21] Cost-Effectiveness of Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC
Mehra, Ranee
Yong, Candice
Seal, Brian
van Keep, Marjolijn
Raad, Angie
Zhang, Yiduo
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (02): : 153 - +
[22] Bronchomediastinal Fistula During Durvalumab Therapy After Chemoradiotherapy in Stage III NSCLC
Sumi, Toshiyuki
Ikeda, Takumi
Kure, Kenichi
Yamada, Yuichi
Nakata, Hisashi
Mori, Yuji
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : 1860 - 1861
[23] Durvalumab after Chemoradiotherapy is currently the most promising Therapy in Stage III NSCLC
Wilhelm, Martin
STRAHLENTHERAPIE UND ONKOLOGIE, 2019, 195 (07) : 691 - 692
[24] Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC
Vansteenkiste, Johan F.
Naidoo, Jarushka
Faivre-Finn, Corinne
Ozguroglu, Mustafa
Villegas, Augusto
Daniel, Davey
Murakami, Shuji
Hui, Rina
Lee, Ki Hyeong
Cho, Byoung Chul
Kubota, Kaoru
Broadhurst, Helen
Wadsworth, Catherine
Newton, Michael
Thiyagarajah, Piruntha
Antonia, Scott J.
JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (03):
[25] Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy
Aredo, Jacqueline V.
Mambetsariev, Isa
Hellyer, Jessica A.
Amini, Arya
Neal, Joel W.
Padda, Sukhmani K.
McCoach, Caroline E.
Riess, Jonathan W.
Cabebe, Elwyn C.
Naidoo, Jarushka
Abuali, Tariq
Salgia, Ravi
Loo Jr, Billy W.
Diehn, Maximilian
Han, Summer S.
Wakelee, Heather A.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (06) : 1030 - 1041
[26] COST-EFFECTIVENESS OF DURVALUMAB FOLLOWING CHEMORADIOTHERAPY IN UNRESECTABLE STAGE III NSCLC PATIENTS IN THE US: AN UPDATE BASED ON 5-YEAR PACIFIC DATA
Mooradian, M. J.
Taylor, S.
Ramsden, R.
van Keep, M.
Dunlop, W.
Brannman, L.
Yong, C.
VALUE IN HEALTH, 2022, 25 (01) : S108 - S108
[27] PACIFIC-6: A Phase II Study of Durvalumab Following Sequential Chemoradiotherapy in Patients with Stage III, Unresectable NSCLC
Garassino, M.
Faivre-Finn, C.
Mazieres, J.
Reck, M.
Emeribe, U.
Franks, A.
Trunova, N.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S403 - S404
[28] Impact of Lymphopenia Recovery After Chemoradiotherapy on Durvalumab Consolidation Therapy in Stage III NSCLC
Kuge, Tomoki
Shiroyama, Takayuki
Tamiya, Akihiro
Tamiya, Motohiro
Kanazu, Masaki
Kinehara, Yuhei
Tanaka, Tsunehiro
Morimura, Osamu
Taniguchi, Yoshihiko
Niki, Toshie
Tetsumoto, Satoshi
Hayashi, Kazuhiko
Nishino, Kazumi
Nagatomo, Izumi
Kumanogoh, Atsushi
JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (05):
[29] Phase 3 trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8).
Ozguroglu, Mustafa
Levy, Benjamin Philip
Horinouchi, Hidehito
Yu, Jinming
Grainger, Ellie
Phuong, Patrick Hoang
Peterson, Daniel
Newton, Michael David
Spira, Alexander I.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[30] Real-World Outcomes with Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFRMutated NSCLC (PACIFIC-R)
Peters, S.
Christoph, D. C.
Field, J. K.
Fietkau, R.
Filippi, A. R.
Garassino, M.
Garrido, P.
McDonald, F.
Mornex, F.
Markman, B.
Solomon, B. J.
Anand, S.
Chander, P.
Qiao, Y.
Girard, N.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S83 - S83

← 1 2 3 4 5 →